Home
Loading

aVenture is in Alpha: During this preview period, you should expect the research data to be limited and may not yet meet our exacting standards. We've made the decision to provide early access to our data to showcase the product as we build, but you should not yet rely upon it alone for your investment decisions.

aVenture is in Alpha: During this preview period, you should expect the research data to be limited and may not yet meet our exacting standards. We've made the decision to provide early access to our data to showcase the product as we build, but you should not yet rely upon it alone for your investment decisions.

Get in touch

  • Contact

  • Request a demo

  • Request data updates

  • Add a company

Research

  • Companies

  • Investors

  • People

aVenture

  • Sitemap

  • Feature requests

Member

Backed by

© aVenture Investment Company, 2026. All rights reserved.

San Francisco, CA, USA

Privacy Policy

aVenture Investment Company ("aVenture") is an independent research platform providing detailed analysis and data on startups, venture capital investments, and key industry individuals. It is not a registered investment adviser, broker-dealer, or investment advisor and does not provide investment advice or recommendations. The data provided by aVenture does not constitute recommendations or advice, whether by methodology, analysis, AI-generated content, or a statement written by a staff member of aVenture.

aVenture is not affiliated with any of the people, companies, organizations, government agencies, regulatory bodies, or investment funds we provide coverage for on this site unless explicitly stated otherwise. Users assume full responsibility for decisions made based on information obtained from this platform. Links to external websites do not imply endorsement or affiliation with aVenture. Any links that provide the ability to invest in a primary or secondary transaction in a company are for convenience only and do not constitute solicitations or offers to buy or sell an investment. Investors should exercise heightened precaution and due diligence when investing in private companies, especially those not independently audited.

While we strive to provide valuable insights with objectivity and professional diligence, we cannot guarantee the accuracy of the information provided on our platform. Before making any investment decisions, you should verify the accuracy of all pertinent details for your decision. To the fullest extent permitted by law, aVenture shall not be liable for any direct, indirect, incidental, consequential, or financial damages arising from use of this site, whether by consumers of its contents directly or by persons or organizations covered by our research, even if we are advised of the possibility. Our best-efforts processes and correction request forms do not create a warranty or duty of care.

Profiles on this platform may include content generated in part by large language models (LLMs, artificial intelligence) that aggregate publicly available sources (e.g., SEC EDGAR, public filings, press releases). Source attribution is provided where known; always verify statements and claims here against original sources before relying on any data. Content on our site may contain inaccuracies, omissions, or what are commonly called 'hallucinations' if generated in part or in full by AI / LLMs. The risk can also exist even when content is written by a human, as internal and third-party sources may also have inaccuracies for the same or different reasons. While we randomly audit a proportion of content, this is not exhaustive.

We recommend that an independent auditor be hired to verify the accuracy of the information before relying on it for any sensitive decisions. By accessing this platform, you agree not to rely solely on any information generated by AI, aggregated, or sourced or written otherwise on this site, for investment, financial, or other decisions. aVenture assumes no responsibility for inaccuracies, omissions, or hallucinations. You must independently verify all data from primary sources. Use of this platform constitutes your waiver of claims for reliance-based damages, including negligent misrepresentation. To report an error, request a correction, or dispute information about a company or individual, contact us via our request data updates form.

Loading homepage
Loading
Loading
Home›
Research›
People›
Adam Gridley
AddedFeb 15, 2024
UpdatedMay 31, 2026
Adam Gridley

Adam Gridley

Board Member, LifeSprout

CrunchbaseLinkedInThe Org

Adam Gridley's Career

LifeSprout
LifeSprout

Baltimore, MD, US

Board Member· Board
Allay Therapeutics
Allay Therapeutics

Menlo Park, CA, US

CEO· C-Suite · Management

Create your profile now and gain access to exclusive deals and high-potential startups.

aVenture product preview
aVenture product preview
aVenture product preview

Adam Gridley's Career

LifeSprout
LifeSprout
Series A$35.8M102015Baltimore, MD, US
Board Member· Board

Leadership at LifeSprout

Sashank ReddySashank ReddyCo-Founder
Michael KrandaMichael KrandaCEO
Russell MartinRussell MartinCo-Founder
Hai-Quan MaoHai-Quan MaoCo-Founder
Justin SacksJustin SacksCo-Founder

Similar to LifeSprout

inSoma BioinSoma BioDurham, NC, USMedical Devicesest. 2018inSoma BioDurham, NC, US · est. 2018

InSoma Bio: Innovating natural solutions for reconstructive plastic surgery using patient's own tissue.

Seed · $3.1M5
TissueFormTissueFormBoulder, CO, USBiomaterialsest. 2019TissueFormBoulder, CO, US · est. 2019

TissueForm: Advancing biomaterials for regenerative medicine and plastic surgery solutions.

Angel · $250k2
HistogenHistogenSan Diego, CA, USMedical Technologiesest. 2007HistogenSan Diego, CA, US · est. 2007

San Diego-based Histogen Inc. innovates patented medical technologies for aesthetic and therapeutic tissue replacement.

Public · $87.5M7
BioAestheticsBioAestheticsNew Orleans, LA, USMedical Devicesest. 2015BioAestheticsNew Orleans, LA, US · est. 2015

BioAesthetics provides innovative breast reconstruction solutions post-mastectomy with a tissue-engineered nipple-areolar complex.

Series A · $6.7M13
Allay Therapeutics
Allay Therapeutics
Series C$118.9M562017Menlo Park, CA, US
CEO· C-Suite · Management

Leadership at Allay Therapeutics

Josh MakowerJosh MakowerBoard Member
Nicole VitulloNicole VitulloBoard Member
Hanson GiffordHanson GiffordFounder

Similar to Allay Therapeutics

Allyx TherapeuticsAllyx TherapeuticsNew Haven, CT, USTherapeuticsest. 2018Allyx TherapeuticsNew Haven, CT, US · est. 2018

Allyx Therapeutics: Clinical-stage biotech firm developing therapies to combat Alzheimer's disease.

Seed · $10.1M4
Amalgent TherapeuticsAmalgent TherapeuticsChapel Hill, NC, USPain Medicationsest. 2020Amalgent TherapeuticsChapel Hill, NC, US · est. 2020

Amalgent Therapeutics: Innovating safer, effective analgesia alternatives to opioids since 2020.

Angel · $450k2
DoloromicsDoloromicsMenlo Park, CA, USBiomarkers, Pain Therapeuticsest. 2020DoloromicsMenlo Park, CA, US · est. 2020

Doloromics: A Dallas-based company innovating in pain therapeutics discovery and disease-specific solutions.

Seed · $7.7M7
Concentric AnalgesicsConcentric AnalgesicsSan Francisco, CA, USTherapeuticsest. 2014Concentric AnalgesicsSan Francisco, CA, US · est. 2014

Concentric Analgesics, Inc.: A biotech firm innovating non-opioid solutions for acute and chronic pain.

Series B · $103.1M22

Adam Gridley's Similar Executives & Operators

Soemantri BrodjonegoroSoemantri BrodjonegoroBoard Member · BukalapakLau Eng BoonLau Eng BoonBoard Member · BukalapakWillix HalimWillix HalimCEO · BukalapakJay Geoffrey WacherJay Geoffrey WacherBoard Member · BukalapakWILL WEI CHENGWILL WEI CHENGBoard Member · DiDiDhirubhai H. AmbaniDhirubhai H. AmbaniBoard Member · Reliance RetailMason YeoMason YeoBoard Member · KakaoJaeHong ChoiJaeHong ChoiBoard Member · Kakao

People Similar to Adam Gridley

Leighton ReadLeighton ReadBoard Member · Cambrios TechnologiesStephen BlochStephen BlochBoard Member · LiquidiaDouglas HayDouglas HayCEO · Allinaire TherapeuticsMike CarusiMike CarusiBoard Member · GlumetricsAdam RosenbergAdam RosenbergCEO · Aliada Therapeutics